Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene Cream, 0.005%

capital market | Mumbai |


Glenmark Pharmaceuticals announced that Glenmark Pharmaceuticals Inc., United States has been granted tentative approval by the United States Food & Drug Administration for Calcipotriene Cream, 0.005%, the therapeutic equivalent of Dovonex Topical Cream, 0.005% of Leo Pharma A/S. Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA. The patents listed in the Orange Book of Dovonex Cream are scheduled to expire on 19 June 2015.

Powered by Capital Market - Live News



  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.